BreathEazy to champion respiratory health at BSAVA Congress

BreathEazy, the leading UK provider of veterinary nebulisers and the AeroKat® and AeroDawg® spacer devices, is set to return to BSAVA after a successful 12 months, which has seen the company go from strength to strength. The company’s growth is in part down to a growing recognition of the benefits of inhaled medication for the management of respiratory disease and also the changing pet owner demographic which has seen today’s pet parents seeking to invest in their pets’ health.

Administering medication by inhalation, either through the use of metered dose inhalers (MDIs) with a spacer, or by nebulisation, enables the targeted delivery of pharmaceutical agents to the lungs and lower airways, with far fewer of the endocrine and immune side effects associated with systemic medication. This has revolutionised the management of companion animal respiratory diseases, including feline asthma.

Jon Slattery MRCVS, Director of BreathEazy, explains, “By directly targeting the site of disease pathology, inhaled therapy achieves the same therapeutic effect as systemic medication but with substantially lower doses and improved outcomes for patients.”

For optimal benefit, spacers and nebulisers need to be tailored to the species in question. This is underscored by a recent study which evaluated various commercially available spacers, including the AeroKat® Chamber and a human paediatric device.¹ Among the tested devices, the AeroKat® had consistently superior drug availability, delivering up to 193 times more medication to the lower airways compared to the other devices.

In the current financial climate household budgets are tight and human paediatric devices may be a tempting option for pet owners. However, technology that is tailored for companion animals can ultimately lead to better control of clinical signs and improved outcomes. Moreover, investing in respiratory health not only improves the quality of life for pets but can also contribute to long-term savings in terms of medication costs for pet owners.

BreathEazy’s commitment to advancing respiratory care for companion animals has been instrumental in its success over the past year. At BSAVA, the company will be showcasing its range of small animal respiratory technology, including the AeroKat® and AeroDawg® spacer devices and the Flexineb® C2 companion animal nebuliser. Delegates are encouraged to visit stand D401 to find out how the company’s innovative solutions can enhance the management of a number of respiratory conditions including feline asthma, canine chronic bronchitis and tracheal collapse.

To find out more about how inhaled therapies can benefit your patients, come and see us on stand D401 or visit breatheazy.co.uk.

Press contact: Katy Ellison, katy@companionconsultancy.com, Tel 07596 217372

About AeroKat®

The AeroKat® Chamber is a spacer device tailored to the needs of feline asthma patients.

• Two mask sizes to cater for all sizes of cat and all face shapes
• Low resistance valve designed for the respiratory flows of cats, keeping medication in the chamber, while still being sensitive enough to open during respiratory distress
• Anti-static chamber increases drug delivery efficiency by up to 40%²
• Longer holding times allow time for smaller feline lung capacities to empty the chamber
• Flow-Vu® indicator moves with inhalation, helping track breaths taken and confirming a proper mask seal.

About AeroDawg®

The AeroDawg® Chamber is a spacer device tailored to the needs of canine respiratory patients, including those with chronic bronchitis, allergic airway disease and tracheal collapse.

• Three mask sizes to cater for all sizes of dog and all face shapes
• Purpose designed valve tailored to the weight and tidal volume of the particular patient for minimal resistance to flow
• Anti-static chamber increases drug delivery efficiency by up to 40%²
• Longer holding times allow time for smaller lung capacities to empty the chamber
• Flow-Vu® indicator moves with inhalation, helping track breaths taken and confirming a proper mask seal.

About Flexineb® C2 nebuliser

The Flexineb® C2 nebuliser is a portable, re-usable, silent nebuliser that converts liquid medications and natural therapies into a fine aerosol for inhalation by small animals. The Flexineb® C2 uses vibrating mesh technology for faster treatment times and can be used in the management of a number of conditions, including feline asthma and allergic rhinitis in cats and chronic bronchitis and laryngeal paralysis in dogs. The device can also be used with a cage mount bracket for direct nebulisation into a kennel or basket.

References

1. Nagel, M., Hoffman, N. and Sartori, S. (2022) Effectiveness of pediatric inhaler chambers in cats with asthma. ACVIM. Trudell Animal Health
2. Trzil J. E. (2020). Feline asthma: diagnostic and treatment update. The Veterinary Clinics of North America. Small animal practice, 50:2, 375-391

About BreathEazy

BreathEazy provides a range of technological veterinary solutions to support the management of respiratory diseases in horses, dogs, cats, birds and exotics. Founded and run by a veterinary surgeon, the goal of improving respiratory health for animals, is at the heart of everything the company does.

As the official UK distributor of the AeroKat®, AeroDawg®, AeroHippus® and Flexineb® range of products, BreathEazy supplies direct to both veterinary clinics and pet owners.

From feline asthma to canine chronic bronchitis and equine respiratory disease, look no further than BreathEazy’s solutions to help support respiratory health in companion animals.

www.breatheazy.co.uk